Drug intelligence / Profile preview

ath-399a

Development stage: Phase 1
Lead developer: NurrOn Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

ATH-399A is a small molecule drug developed as a Nurr1 (nuclear receptor subfamily 4 group A member 2) activator for the potential treatment of Parkinson’s disease. It is designed to boost the activity of dopamine-producing nerve cells in the brain by targeting Nurr1, which plays a critical role in maintaining these cells. The drug has completed Phase 1 clinical trials in healthy volunteers and demonstrated a favorable safety profile with no major safety issues reported across multiple dose levels. Pharmacokinetic data support once-daily oral dosing. The next planned step is to evaluate its efficacy and safety in patients with Parkinson’s disease[2][5][6].

Other names: ATH 399AATH399AATH-399ADWP 307399DWP307399DWP-307399HL-192HL192HL 192

Targets

NR4A2 (Nuclear receptor subfamily 4 group A member 2)

Beyond the preview

Go deeper on ath-399a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ath-399a.

Explore the full profile